Regulations.gov document
Tab 7 - Corrado Blandizzi et al. - Impact of Crystal Polymorphism on the Systemic…
Supporting & Related Material · FDA-2021-P-0096 · posted Feb 3, 2021
Key facts
| Document ID | FDA-2021-P-0096-0006 |
|---|---|
| Title | Tab 7 - Corrado Blandizzi et al. - Impact of Crystal Polymorphism on the Systemic Bioavailability of Rifaximin, an Antibiotic Acting Locally in the Gastrointestinal Tract, in Healthy Volunteers RE Citizen Petition from BakerHostetler LLP (on behalf of Salix Pharmaceuticals Inc) |
| Document type | Supporting & Related Material |
| Subtype | Background Material |
| Agency | FDA |
| Docket | FDA-2021-P-0096 |
| Posted | Feb 3, 2021 |
At a glance
- 1–9 Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: